Uriten

COMPOSITION
Each Uriten â extended release tablet contains 10 mg Alfuzosin hydrochloride BP as the active ingredient.

PHARMACOLOGY
The symptoms associated with benign prostatic hyperplasia (BPH) such as urinary frequency, nocturia, weak stream, hesitancy and incomplete emptying are related to two components, anatomical (static) and functional (dynamic). The static component is related to the prostate size. But prostate size alone does not correlate with symptom severity. The dynamic component is a function of the smooth muscle tone in the prostate and its capsule, the bladder neck and the bladder base as well as the prostatic urethra. The smooth muscle tone is regulated by alpha-adrenergic receptors. Alfuzosin is an orally active quinazoline derivative, peripherally acting antagonist, exhibits selectivity for postsynaptic alpha-1 adrenergic receptors in the lower urinary tract. Blockade of these adrenoceptors can cause smooth muscle in the bladder neck and prostate to relax, resulting in an improvement in urine flow and a reduction in symptoms of BPH.

INDICATION
Uriten is used for the treatment of functional symptoms of Benign Prostatic Hyperplasia (BPH). It is also used as a short term treatment of acute urinary retention (AUR) related to BPH patients (over 65 years) in association with catheterization.

DOSAGE AND ADMINISTRATION
BPH: Uriten â 10 mg once daily immediately after the same meal each day.
AUR: Uriten â 10 mg once daily immediately after the same meal each day. Dose should be started from the first day of catheterization. The treatment should be continued for 3-4 days (2-3 days during catheterization and 1 day after its removal).
The tablet should be swallowed whole. The tablets should not be chewed or crushed. These actions may lead to an inappropriate release and absorption of the drug and therefore possible early adverse reaction.

CONTRAINDICATION
Hypersensitivity to Alfuzosin, history of orthostatic hypotension, moderate and severe liver problem, in combination with other alpha-blockers. This is contraindicated for use in women and children (under the age 18).

SIDE EFFECTS
Dizziness, Headache, Fatigue, Vertigo, Malaise, Tachycardia, Palpitation, Nausea, Abdominal pain, Rash, Diarrhea, Postural hypotension, Syncope, Dry mouth.

OVERDOSE

Symptoms of an overdose of Alfuzosin may include low blood pressure. In case of over dosage, the patient should be hospitalized, kept in the supine position and conventional treatment of hypotension should take place. Alfuzosin is not dialyzable because of its high protein binding (82% to 90%).

DRUG INTERACTION
Alfuzosin may interact with other alpha-blockers, Atenolol, Cimetidine, Diltiazem, Ketoconazole and Ritonavir.

WARNING
The administration of general anesthetics to patients receiving Alfuzosin could cause profound hypotension. It is recommended that the tablets be withdrawn 24 hours before surgery. If symptoms of angina pectoris start or get worse, taking Alfuzosin should be stopped.

USE IN PREGNANCY AND LACTATION
Alfuzosin should not be used by women.

STORAGE
Store in a dry place protected from light and moisture. Keep out of reach of children.

HOW SUPPLIED
Uriten â ER Tablet: Box containing 3x10 tablets.